Milestone Pharmaceuticals...

AI Score

XX

Unlock

0.70
-0.05 (-6.67%)
At close: Apr 04, 2025, 3:48 PM

Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines.

The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans.

The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. logo
Country CA
IPO Date May 9, 2019
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Joseph G. Oliveto M.B.A.

Contact Details

Address:
1111 Dr. Frederik-Philips Boulevard
Montreal, QC
CA
Website https://www.milestonepharma.com

Stock Details

Ticker Symbol MIST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001408443
CUSIP Number 59935V107
ISIN Number CA59935V1076
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Joseph G. Oliveto M.B.A. Chief Executive Officer, President & Director
Amit Hasija Chief Financial Officer & Executive Vice President of Corporate Development
Jeffrey Nelson Chief Operating Officer
Dr. David B. Bharucha FACC, M.D., Ph.D. Chief Medical Officer
Dr. Guy Rousseau SVice President of Regulatory Affairs and Quality Management
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. Chief Medical Advisor & Member of the Scientific Advisory Board
Dr. Philippe Douville M.B.A., Ph.D. Founder, Strategic Advisor & Member of Scientific Advisory Board
Jeff Moore Vice President of Sales
Kim Fox Vice President of Communications
Roshan Girglani Vice President of Marketing

Latest SEC Filings

Date Type Title
Mar 28, 2025 8-K Current Report
Mar 19, 2025 8-K Current Report
Mar 18, 2025 424B5 Filing
Mar 18, 2025 8-K Current Report
Mar 13, 2025 S-8 Filing
Mar 13, 2025 8-K Current Report
Mar 13, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 05, 2025 SCHEDULE 13G/A [Amend] Filing